🇺🇸 FDA
Company

Can-Fite

Can-Fite BioPharma

CANF biotech USA

Quick answer

Can-Fite is a biotech company (CANF) headquartered in RAMAT GAN, L3, USA with 18 tracked pipeline programs.

Pipeline (18)

project

CF101

Plaque Psoriasis

Phase 3 · small_molecule · completed

1 trials project

CF101

Keratoconjunctivitis Sicca

Phase 3 · small_molecule · completed

2 trials project

CF101 1 mg

Rheumatoid Arthritis

Phase 3 · small_molecule · terminated

1 trials project

CF101 2mg

Plaque Psoriasis

Phase 3 · small_molecule · completed

1 trials project

Namodenoson

Hepatocellular Carcinoma

Phase 3 · small_molecule · active

1 trials project

piclidenoson

Plaque Psoriasis

Phase 3 · small_molecule · active

1 trials project

CF 102

Chronic Hepatitis C

Phase 2 · small_molecule · completed

1 trials project

CF101

Ocular Hypertension

Phase 2 · small_molecule · completed

1 trials project

CF101

Rheumatoid Arthritis

Phase 2 · small_molecule · completed

3 trials project

CF101

Uveitis, Posterior

Phase 2 · small_molecule · terminated

1 trials project

CF101

Osteoarthritis of the Knee

Phase 2 · small_molecule · terminated

1 trials project

CF101 1mg

Plaque Psoriasis

Phase 2 · small_molecule · completed

1 trials project

CF102

Non-alcoholic Steatohepatitis (NASH)

Phase 2 · small_molecule · completed

1 trials project

CF102

Hepatocellular Carcinoma

Phase 2 · small_molecule · completed

2 trials project

Namodenoson

NASH - Nonalcoholic Steatohepatitis

Phase 2 · small_molecule · active

1 trials project

Namodenoson 25mg

Pancreatic Adenocarcinoma

Phase 2 · small_molecule · active

1 trials project

Piclidenoson

COVID-19

Phase 2 · small_molecule · completed

1 trials project

Piclidenoson

Lowe Syndrome

Phase 2 · small_molecule · active

1 trials

Patents (8)

patent

US 12213990

A3 adenosine receptor ligand for use for achieving a fat loss effect

Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11291681

Method for treating fibrotic liver tissue using Cl-IB-MECA

Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10780106

Method for treating NASH accompanied by fibrosis using Cl-IB-MECA

Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10265337

Use of A3 adenosine receptor agonist in osteoarthritis treatment

Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9549943

A3 adenosine receptor ligands for use in treatment of a sexual dysfunction

Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9387220

Method for inducing hepatocyte proliferation and uses thereof

Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 9102698

Process for the synthesis of IB-MECA

Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 8987228

Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1

Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)